Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
2008 Standout
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2014
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
miR-15 and miR-16 induce apoptosis by targeting BCL2
2005 Standout
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2014
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
2016
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
2015
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
2012
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
2015
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B‐cell lymphoma
2002
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
2006
The Clinical Significance of CD10 Antigen Expression in Diffuse Large B-Cell Lymphoma
2001
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Predictive validity of a frailty measure (GFI) and a case complexity measure (IM-E-SA) on healthcare costs in an elderly population
2015
Clinicopathologic Analysis of CD10+ and CD10– Diffuse Large B-Cell Lymphoma
2001
Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence
2004
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Founder Effect at PGL1 in Hereditary Head and Neck Paraganglioma Families from The Netherlands
1998
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case–control study of overall survival
2013
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
2002 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
2004
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis
2001
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
2003
A molecular signature of metastasis in primary solid tumors
2002 Standout
Signalling pathways of the TNF superfamily: a double-edged sword
2003 Standout
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
2017
Immunohistochemical Expression Patterns of Germinal Center and Activation B-cell Markers Correlate With Prognosis in Diffuse Large B-cell Lymphoma
2004
Acne vulgaris
2011 Standout
Follicular lymphoma international prognostic index
2006
Drug-Induced Skin, Nail and Hair Disorders
2007
Subclinical Atrial Fibrillation and the Risk of Stroke
2012
Apoptosis
2002 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
2012
Frailty: implications for clinical practice and public health
2019 Standout
Death and anti-death: tumour resistance to apoptosis
2002 Standout
Reflecting on 25 years with MYC
2008 Standout
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
2003 Standout
The Myc oncoprotein as a therapeutic target for human cancer
2006
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
2004
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: Current and future evidence
2015
Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy
2006 Standout
Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
2011
Rearrangements of Bcl-1, Bcl-2, Bcl-6, and C-Myc in Diffuse Large B-Cell Lymphomas
2001
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
2015 Standout
CD10 and BCL-6 Expression in Paraffin Sections of Normal Lymphoid Tissue and B-Cell Lymphomas
2000
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
2021 Standout
Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
2013
Primary and Secondary Cutaneous Diffuse Large B-Cell Lymphomas
2003
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
2001
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
2006 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
The AP1-dependent secretion of galectin-1 by Reed–Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
2007 Standout
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Nonimmunoglobulin (non-Ig)/BCL6gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6
2000
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
2006
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
2011
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
2006 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Breast Cancer Treatment
2019 Standout
Transcriptional control of human p53-regulated genes
2008 Standout
The role of radiotherapy in cancer treatment
2005 Standout
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Nonimmunoglobulin (non-Ig)/BCL6gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6
2000
Diffuse large cell lymphoma
2011
Cell cycle deregulation in B-cell lymphomas
2003
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study
2012
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
2001
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
2005
Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma
2005
Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin’s Lymphoma
2001
BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma
2005
Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin’s Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively
2005
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
2000 StandoutScience
Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma
2002
Works of E. Maartense being referenced
Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
2009
Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
2011
Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin’slymphoma registry
2002
High non-compliance in the use of letrozole after 2.5years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial
2011
Elderly patients with non-Hodgkin’s lymphoma: Population-based results in the Netherlands
1998
Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age
2000
Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy
2010
Prognostic value of geriatric assessment in older patients with advanced breast cancer receiving chemotherapy
2013
Lack of Prognostic Significance of BCL2 and p53 Protein Overexpression in Elderly Patients with Diffuse Large B-cell Non-Hodgkin's Lymphoma: Results from a Population-based Non-Hodgkin's Lymphoma Registry
2003
Hypothyroidism and chemodectoma in father and daughter: a new syndrome of a coincidence?
1992
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
2014
Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
1998
Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma
1998
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
2017
Abstract P1-12-05: First-line chemotherapy with pegylated liposomal doxorubicin versus capecitabine in elderly patients with metastatic breast cancer: results of the phase III OMEGA study of the Dutch Breast Cancer Trialists' Group (BOOG)
2012
[Erythema multiforme vs. Stevens-Johnson syndrome and toxic epidermal necrolysis: an important diagnostic distinction].
2003